<div class="pk-crumbs" data-crumbs="[{&quot;label&quot;:&quot;Drugs&quot;,&quot;href&quot;:&quot;README.md&quot;},{&quot;label&quot;:&quot;B02A&quot;,&quot;href&quot;:&quot;atc/B02A.md&quot;},{&quot;label&quot;:&quot;tranexamic acid&quot;}]"></div>
<div class="pk-recnav" data-items="[{&quot;id&quot;:&quot;TranexamicAcid_Li2021_reference&quot;,&quot;label&quot;:&quot;Li_2021_reference&quot;,&quot;group&quot;:&quot;popPK&quot;,&quot;href&quot;:&quot;drugs/drug_tranexamic_acid/TranexamicAcid_Li2021_reference.md&quot;,&quot;status&quot;:&quot;reviewed \u2014 candidate&quot;,&quot;css&quot;:&quot;pk-badge--green&quot;,&quot;here&quot;:false},{&quot;id&quot;:&quot;TranexamicAcid_Gilliot2022_reference&quot;,&quot;label&quot;:&quot;Gilliot_2022_reference&quot;,&quot;group&quot;:&quot;popPK&quot;,&quot;href&quot;:&quot;drugs/drug_tranexamic_acid/TranexamicAcid_Gilliot2022_reference.md&quot;,&quot;status&quot;:&quot;needs review&quot;,&quot;css&quot;:&quot;pk-badge--orange&quot;,&quot;here&quot;:false}]"></div>

# tranexamic acid

- **generic name:** tranexamic acid
- **ATC codes:** `B02AA02`
- **DrugBank:** [DB00302](https://go.drugbank.com/drugs/DB00302) · **PubChem:** [CID 5526](https://pubchem.ncbi.nlm.nih.gov/compound/5526)
- **molar mass:** 157.2102 g/mol (C8H15NO2) — DrugBank
- **groups:** approved, investigational

## About

Tranexamic acid is an antifibrinolytic medicine used to treat or prevent bleeding, including conditions such as subarachnoid hemorrhage and blood coagulation disorders. It is widely used and is included on the WHO list of essential medicines, and it is also being investigated for additional uses.

<small>Summary written by `glm-5.3-flash` from [Wikidata Q418666](https://www.wikidata.org/wiki/Q418666) and the WHO ATC classification; not checked by a person.</small>

## Molecules and molar masses

> The molar mass each model uses to convert mass to molar concentration and to form a metabolite molecule for molecule. Looked up, never estimated: DrugBank for the drug, the paper's own value or the PubChem entry matched to the paper's name for a metabolite.

| molecule | role | molar mass (g/mol) | formula | source | PubChem | records |
|---|---|---|---|---|---|---|
| tranexamic acid (tranexamic_acid) | parent | 157.21 | C8H15NO2 | DrugBank | [5526](https://pubchem.ncbi.nlm.nih.gov/compound/5526) | Dunn_2025, Gilliot_2022, Li_2021, Liu_2025 |

## Extraction summary

| extracted at | time | popPK e/r/o | PD e/r/o (paper) | PGx e/r/o | tokens in/out | LLM | papers | GROBID/JATS | OA/non-OA | NONMEM |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-05 17:16 | 16:28 | 1/4/1 | 3/0/1 | 0/0/0 | 283,531/49,516 | ollama / qwen3.8:27b-mtp-q8_0 | 9 | 1/8 | 9/0 | 0 |

## popPK records

| status | detail | model | model structure | params | citation | doi |
|---|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--green">reviewed — candidate</span> <span class="pk-badge pk-badge--red" title="re-read by gpt-oss:120b (not confirmed, agreement 0.167). The first reading is what the record holds.">cross-check: disputed</span> | [Li_2021_reference](drugs/drug_tranexamic_acid/TranexamicAcid_Li2021_reference.md) | ▶ model + simulator | 2-compartment, IV | 4 | Li S et al., Population pharmacokinetics and pharmac…, British journal of clinical… (2021) | [10.1111/bcp.14767](https://doi.org/10.1111/bcp.14767) |
| <span class="pk-badge pk-badge--orange">needs review</span> <span class="pk-badge pk-badge--red" title="re-read by gpt-oss:120b (not confirmed, agreement 0.133). The first reading is what the record holds.">cross-check: disputed</span><br><sub>caveat: the record defines covariate effects (weight on clearance, renal function …) but the engineer simulated only…</sub><br><sub>blocking: T1_t_half_terminal</sub><br><sub>route_to: `scholar`</sub> | [Gilliot_2022_reference](drugs/drug_tranexamic_acid/TranexamicAcid_Gilliot2022_reference.md) | ▶ model + simulator | 2-compartment, IV | 4 | Gilliot S et al., Pharmacokinetics of Curative Tranexamic…, Pharmaceutics (2022) | [10.3390/pharmaceutics14030578](https://doi.org/10.3390/pharmaceutics14030578) |
| <span class="pk-badge pk-badge--red">rejected</span> <span class="pk-badge pk-badge--red" title="re-read by gpt-oss:120b (not confirmed, agreement 0.5). The first reading is what the record holds.">cross-check: disputed</span><br><sub>blocking: missing key parameters — none reported by this paper</sub><br><sub>route_to: `human_review`</sub> | [Dowd_2002_reference](drugs/drug_tranexamic_acid/TranexamicAcid_Dowd2002_reference.md) | — | 1-compartment (no model) | 0 | Dowd NP et al., Pharmacokinetics of tranexamic acid dur…, Anesthesiology (2002) | [10.1097/00000542-200208000-00016](https://doi.org/10.1097/00000542-200208000-00016) |
| <span class="pk-badge pk-badge--red">rejected</span> <span class="pk-badge pk-badge--stale">stale</span> <span class="pk-badge pk-badge--red" title="re-read by gpt-oss:120b (not confirmed, agreement 0.467). The first reading is what the record holds.">cross-check: disputed</span><br><sub>STALE — current validate: rejected</sub><br><sub>blocking: C8 unreachable/orphan compartment or unlinked metabolite</sub><br><sub>route_to: `human_review`</sub> | [Dunn_2025_reference](drugs/drug_tranexamic_acid/TranexamicAcid_Dunn2025_reference.md) | — | 2-compartment (no model) | 5 (+2 cov.) | Dunn A et al., Evaluating Tranexamic Acid Dosing Strat…, Journal of clinical pharmac… (2025) | [10.1002/jcph.70031](https://doi.org/10.1002/jcph.70031) |
| <span class="pk-badge pk-badge--red">rejected</span> <span class="pk-badge pk-badge--stale">stale</span> <span class="pk-badge pk-badge--red" title="re-read by gpt-oss:120b (not confirmed, agreement 0.833). The first reading is what the record holds.">cross-check: disputed</span><br><sub>STALE — current validate: rejected</sub><br><sub>blocking: C8 unreachable/orphan compartment or unlinked metabolite</sub><br><sub>route_to: `human_review`</sub> | [Liu_2025_estimate_rse](drugs/drug_tranexamic_acid/TranexamicAcid_Liu2025_estimate_rse.md) | — | 2-compartment (no model) | 3 | Liu Y et al., Population Pharmacokinetics of Tranexam…, Drug design, development an… (2025) | [10.2147/DDDT.S493485](https://doi.org/10.2147/DDDT.S493485) |
| <span class="pk-badge pk-badge--red">rejected</span> <span class="pk-badge pk-badge--red" title="re-read by gpt-oss:120b (not confirmed, agreement 0.75). The first reading is what the record holds.">cross-check: disputed</span><br><sub>blocking: C8 unreachable/orphan compartment or unlinked metabolite</sub><br><sub>route_to: `human_review`</sub> | [Liu_2025_the_final_model](drugs/drug_tranexamic_acid/TranexamicAcid_Liu2025_the_final_model.md) | — | 2-compartment (no model) | 3 | Liu Y et al., Population Pharmacokinetics of Tranexam…, Drug design, development an… (2025) | [10.2147/DDDT.S493485](https://doi.org/10.2147/DDDT.S493485) |

## Pharmacodynamics (PD)

| status | detail | about | model | citation | doi |
|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--green">reviewed — candidate</span> | [Li_2021_maximum_lysis](drugs/drug_tranexamic_acid/pd_Li_2021_maximum_lysis.md) | maximum lysis ← tranexamic acid · direct sigmoid Emax (Hill) effect | model (no simulator) | Li S et al., Population pharmacokinetics and pharmac…, British journal of clinical… (2021) | [10.1111/bcp.14767](https://doi.org/10.1111/bcp.14767) |
| <span class="pk-badge pk-badge--green">extracted</span> | [Rozen_2015_LI30](drugs/drug_tranexamic_acid/pd_Rozen_2015_LI30.md) | lysis index after 30 min ← tranexamic acid · direct sigmoid Emax (Hill) effect | — | Rozen L et al., Effective tranexamic acid concentration…, European journal of anaesth… (2015) | [10.1097/EJA.0000000000000316](https://doi.org/10.1097/EJA.0000000000000316) |
| <span class="pk-badge pk-badge--green">extracted</span> | [Zufferey_2021_seizure](drugs/drug_tranexamic_acid/pd_Zufferey_2021_seizure.md) | seizure ← tranexamic acid · stimulation effect | — | Zufferey PJ et al., Exposure-Response Relationship of Trane…, Anesthesiology (2021) | [10.1097/ALN.0000000000003633](https://doi.org/10.1097/ALN.0000000000003633) |
| <span class="pk-badge pk-badge--orange">needs review</span> <span class="pk-badge pk-badge--green" title="re-read by gpt-oss:120b (confirmed, agreement 1.0). The first reading is what the record holds.">cross-checked ✓</span> | [Shakur-Still_2023_D_dimer](drugs/drug_tranexamic_acid/pd_Shakur_Still_2023_D_dimer.md) | D-dimer ← tranexamic acid · indirect response — drug inhibits the production of D-dimer | model (no simulator) | Shakur-Still H et al., Alternative routes for tranexamic acid…, BJOG : an international jou… (2023) | [10.1111/1471-0528.17455](https://doi.org/10.1111/1471-0528.17455) |
| <span class="pk-badge pk-badge--orange">needs review</span> | [Zufferey_2021_postoperative_blood_loss](drugs/drug_tranexamic_acid/pd_Zufferey_2021_postoperative_blood_loss.md) | postoperative blood loss ← tranexamic acid · direct Emax (saturable) effect | model (no simulator) | Zufferey PJ et al., Exposure-Response Relationship of Trane…, Anesthesiology (2021) | [10.1097/ALN.0000000000003633](https://doi.org/10.1097/ALN.0000000000003633) |

## ADME sites

Where this drug is handled, from DrugBank's curated enzymes / transporters / carriers and the KB's PGx genes, mapped to tissue through the ADME gene table. Compare it with other drugs on the [Sites & interactions](sites?drugs=tranexamic_acid) page (add drugs there; the set becomes a link).

| process | tissue | actors (role) | evidence |
|---|---|---|---|
| absorption | small intestine | <sub>named in DrugBank's ADME text</sub> | prose |
| excretion | kidney | <sub>named in DrugBank's ADME text</sub> | prose |

<sub>Actors without a tissue in the table: PLG (inhibitor).</sub>

<details class="legend">
<summary>Badge legend — what each badge means</summary>
<table><thead><tr><th>badge</th><th>what it means</th></tr></thead><tbody><tr><td><span class="pk-badge pk-badge--green">curated</span></td><td>hand-authored by a person — an exemplar, not an extraction.</td></tr><tr><td><span class="pk-badge pk-badge--green">extracted</span></td><td>the pipeline accepted the record: every closed-form check it could run passed.</td></tr><tr><td><span class="pk-badge pk-badge--green">reviewed — candidate</span></td><td>the reviewer ran the built model against the paper's own reported values and they agree — the best automatic verdict there is.</td></tr><tr><td><span class="pk-badge pk-badge--green">accepted (caveats)</span></td><td>the model replicates the paper, but an advisory check failed — the record page names the caveat under the badge and the drug page shows it under the status.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>extracted, then a check failed or a value looks implausible. The numbers are shown as read, not endorsed.</td></tr><tr><td><span class="pk-badge pk-badge--orange">built, not shipped</span></td><td>a model was built, but a core parameter fell back to a library default, so it is not shipped.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>not accepted — the record is not a compartmental model, or nothing usable was extracted.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">not modelled</span></td><td>pipeline state, not a judgement: no model has been built for this record yet (likewise `not simulated`).</td></tr><tr><td><span class="pk-badge pk-badge--stale">stale</span></td><td>the reviewer's verdict predates the latest re-run of the paper — treat the status as out of date, not as current.</td></tr><tr><td><span class="pk-badge pk-badge--green">cross-checked ✓</span></td><td>every independent reader agreed on every compared field. With more than one reader the badge counts them, e.g. 'cross-checked ✓ 2/2'.</td></tr><tr><td><span class="pk-badge pk-badge--orange">cross-check: partial</span></td><td>a reader differs on a non-structural field (a population label, a flag), or the readers do not all agree with each other.</td></tr><tr><td><span class="pk-badge pk-badge--red">cross-check: disputed</span></td><td>at least one reader differs on a structural parameter — a clearance, a volume, ka, a lag. The record still holds the FIRST reading; the disagreement is a signal for a reviewer, never an automatic correction.</td></tr><tr><td><span class="pk-badge pk-badge--species">rat</span></td><td>the data come from an animal (or in-vitro) study, not from people. The record, its model and its simulation are kept — they describe that species.</td></tr></tbody></table>
<p><small>The first badge is the record's <b>status</b> — what the pipeline and the reviewer concluded. A second badge, when present, is the <b>cross-check</b>: whether a model of another family, re-reading the same paper, extracted the same numbers. They are independent — a rejected record can be cross-checked, and a confirmed reading can still fail a plausibility check.</small></p>
</details>

## Coverage

- **PubMed hits:** 58 matched, 28 returned
- **screened:** 6  ·  **relevant:** 6
- **records:** 6  ·  extracted 1  ·  needs_review 1  ·  rejected 4  ·  stale 2
- **scholar-agent fallback query used:** not captured

## Full text wanted

_10 paper(s) judged relevant from the abstract, with no full text on disk — paywalled, or the resolver could not reach them. Follow the DOI, then save the PDF into `papers/` as `&lt;save as&gt;.pdf` and re-run the extraction._

| save as | citation | domain | score | DOI | PubMed | why wanted |
|---|---|---|---|---|---|---|
| `Dowd_2002.pdf` | Dowd NP et al., Pharmacokinetics of tranexamic acid dur…, Anesthesiology (2002) | popPK | 10 | [10.1097/00000542-200208000-00016](https://doi.org/10.1097/00000542-200208000-00016) | [12151929](https://pubmed.ncbi.nlm.nih.gov/12151929) | The paper reports a population pharmacokinetic model for tranexamic acid in humans with specific numeric values for clearance and volume of distribution provided in the abstract. |
| `Gurunathan_2026.pdf` | Gurunathan U et al., A pharmacokinetic/pharmacodynamic analy…, British journal of anaesthe… (2026) | popPK | 10 | [10.1016/j.bja.2024.12.004](https://doi.org/10.1016/j.bja.2024.12.004) | [39848872](https://pubmed.ncbi.nlm.nih.gov/39848872) | The study is a population PK/PD analysis of tranexamic acid in humans, but the specific numeric parameter values (CL, V, Q, etc.) are not listed in the provided abstract text. |
| `Lanoiselée_2018.pdf` | Lanoiselée J et al., Is tranexamic acid exposure related to…, British journal of clinical… (2018) | popPK | 10 | [10.1111/bcp.13460](https://doi.org/10.1111/bcp.13460) | [29193211](https://pubmed.ncbi.nlm.nih.gov/29193211) | The study is a population PK study of tranexamic acid in humans, but the specific numeric parameter values (CL, V, Q) are not listed in the provided abstract text. |
| `Li_2021.pdf` | Li S et al., Population pharmacokinetics and pharmac…, British journal of clinical… (2021) | popPK | 10 | [10.1111/bcp.14767](https://doi.org/10.1111/bcp.14767) | [33576009](https://pubmed.ncbi.nlm.nih.gov/33576009) | The paper reports a population PK model for tranexamic acid with all quantitative parameters (CL, V, Q) explicitly listed in the abstract. |
| `Minamijima_2024.pdf` | Minamijima Y et al., Evaluation of plasma and urine pharmaco…, Journal of veterinary pharm… (2024) | popPK | 10 | [10.1111/jvp.13407](https://doi.org/10.1111/jvp.13407) | [37753811](https://pubmed.ncbi.nlm.nih.gov/37753811) | The study reports quantitative PK parameters (clearance, volume of distribution) for tranexamic acid in horses, with values explicitly stated in the abstract. |
| `Stitt_2024.pdf` | Stitt G et al., Population pharmacokinetic modelling an…, British journal of clinical… (2024) | popPK | 10 | [10.1111/bcp.16075](https://doi.org/10.1111/bcp.16075) | [38697615](https://pubmed.ncbi.nlm.nih.gov/38697615) | The paper describes a population pharmacokinetic model for tranexamic acid in humans, but the specific numeric parameter values (CL, V, etc.) are not present in the provided evidence text. |
| `Zufferey_2021.pdf` | Zufferey PJ et al., Exposure-Response Relationship of Trane…, Anesthesiology (2021) | popPK | 8 | [10.1097/ALN.0000000000003633](https://doi.org/10.1097/ALN.0000000000003633) | [33316069](https://pubmed.ncbi.nlm.nih.gov/33316069) | The study uses a population pharmacokinetic model to predict tranexamic acid exposures, but the specific PK parameter values (CL, V, etc.) are not explicitly listed in the provided evidence, only the resulting exposure-response metrics (EC50). |
| `Rozen_2015.pdf` | Rozen L et al., Effective tranexamic acid concentration…, European journal of anaesth… (2015) | pd | 5 | [10.1097/EJA.0000000000000316](https://doi.org/10.1097/EJA.0000000000000316) | [26258658](https://www.ncbi.nlm.nih.gov/pubmed/26258658) | metadata signals extractable PD data (concentration-effect) |
| `Kristensson_2018.pdf` | Kristensson L et al., Plasminogen binding inhibitors demonstr…, Neuroscience letters (2018) | pd | 4 | [10.1016/j.neulet.2018.05.018](https://doi.org/10.1016/j.neulet.2018.05.018) | [29758302](https://www.ncbi.nlm.nih.gov/pubmed/29758302) | metadata signals extractable PD data (EC50) |
| `Maideen_2021.pdf` | Maideen NMP et al., Pharmacokinetic Approach of Clinically…, Endocrine, metabolic & immu… (2021) | pgx | 7 | [10.2174/1871530320666200820092534](https://doi.org/10.2174/1871530320666200820092534) | [32819252](https://www.ncbi.nlm.nih.gov/pubmed/32819252) | metadata signals extractable PGX data (CYP3A4, PK/PD-context) |

<sub>queue written 2026-10-05T17:01:55.949061+00:00</sub>

## Screened and excluded

| domain | paper | verdict | relevance | extractability | reason |
|---|---|---|---|---|---|
| PGx | Beckman_2020 | not_relevant | 0 | 0 | The study examines the relationship between HHT genotypes and bleeding severity (ESS), not the pharmacokinetics or pharmacodynamics of tranexamic acid. |
| PGx | Castaman_2019 | not_relevant | 0 | 0 | The paper discusses the clinical management of von Willebrand disease during pregnancy and mentions tranexamic acid only as a general prophylactic agent for lochia, without reporting any pharmacogenomic effects on its PK or PD parameters. |
| popPK | Gilliot_2020 | relevant | 10 | 2 | The paper describes a PK study of tranexamic acid in humans and references Table 1 containing individual parameter estimates, but the actual numeric values for CL, V1, V2, and Q are not present in the provided evidence text. |
| popPK | Gurunathan_2026 | relevant | 10 | 2 | The study is a population PK/PD analysis of tranexamic acid in humans, but the specific numeric parameter values (CL, V, Q, etc.) are not listed in the provided abstract text. |
| popPK | Houston_2026 | irrelevant | 0 | 0 | The paper is a clinical trial evaluating the efficacy and safety of tranexamic acid in reducing transfusion needs, not a pharmacokinetic study reporting disposition parameters. |
| PGx | Ihtasham_2025 | not_relevant | 1 | 0 | The paper is a narrative review that mentions pharmacogenomics generally but does not report specific gene variants or quantitative effects on tranexamic acid PK/PD parameters. |
| popPK | Kristensson_2018 | irrelevant | 0 | 0 | The study is an in-vitro mechanistic investigation of receptor binding (GABA/glycine) and does not report pharmacokinetic disposition parameters for tranexamic acid. |
| popPK | Lanoiselée_2018 | relevant | 10 | 2 | The study is a population PK study of tranexamic acid in humans, but the specific numeric parameter values (CL, V, Q) are not listed in the provided abstract text. |
| PD | Lanoiselée_2018 | not_relevant | 4 | 2 | The study performs a PK/PD analysis but explicitly reports that no relationship was found between TXA exposure markers and blood loss, providing no numeric PD parameters or effect-response curve. |
| PGx | Maideen_2021 | not_relevant | 0 | 0 | The paper is a review of drug-drug interactions involving hormonal contraceptives and does not report pharmacogenomic effects on tranexamic acid PK/PD. |
| PGx | Meiring_2011 | not_relevant | 0 | 0 | The paper discusses the diagnosis and management of von Willebrand disease and mentions tranexamic acid as a treatment, but it does not report any pharmacogenomic effects on the pharmacokinetics or pharmacodynamics of tranexamic acid. |
| PGx | ODonnell_2023 | not_relevant | 0 | 0 | The paper is a review of low von Willebrand disease pathobiology and mentions tranexamic acid only as a standard treatment option, without reporting any pharmacogenomic effects on its PK or PD parameters. |
| popPK | Rozen_2015 | irrelevant | 0 | 0 | The study is an in-vitro pharmacodynamic assessment of effective concentrations (EC50/EC95) for fibrinolysis inhibition, not a pharmacokinetic study reporting disposition parameters like clearance or volume. |
| popPK | Shakur-Still_2023 | relevant | 10 | 2 | The paper describes a population PK model for tranexamic acid in humans, but the specific numeric parameter estimates (CL, V, Q, Ka) are located in Table S1 and Figures S2/S3, which are not included in the provided evidence. |
| PGx | Sirgo_2009 | not_relevant | 2 | 5 | The paper reports a pharmacogenomic effect on bleeding (PD) specifically for aprotinin, not tranexamic acid. |
| popPK | Stitt_2024 | relevant | 10 | 0 | The paper describes a population pharmacokinetic model for tranexamic acid in humans, but the specific numeric parameter values (CL, V, etc.) are not present in the provided evidence text. |
| popPK | VanBuren_2021 | irrelevant | 0 | 0 | The paper describes the statistical design of a clinical trial for tranexamic acid efficacy (quality of life outcomes) and does not report pharmacokinetic parameters such as clearance or volume. |
| PD | VanBuren_2021 | not_relevant | 2 | 0 | The paper describes the statistical design (Bayesian adaptive trial using an Emax model) for a future study and uses simulated data for operating characteristics, but it does not report actual observed PD parameters or an empirical dose-response curve from real patient data. |
| popPK | Zufferey_2021 | relevant | 8 | 2 | The study uses a population pharmacokinetic model to predict tranexamic acid exposures, but the specific PK parameter values (CL, V, etc.) are not explicitly listed in the provided evidence, only the resulting exposure-response metrics (EC50). |
| popPK | Zufferey_2025 | irrelevant | 2 | 0 | This is a study protocol for a future clinical trial that does not report original quantitative pharmacokinetic parameter values (CL, V, etc.) for tranexamic acid, only referencing a prior model for dose selection. |

---
<sub>Generated by `docs.py` (scholarv2) · newest extraction 2026-10-05 17:02 UTC</sub>
